Science & Enterprise subscription

Follow us on Twitter

  • National Institutes of Health is organizing a collection of sites for late-stage clinical trials to test Covid-19 v… https://t.co/dXYVebRYMk
    about 6 hours ago
  • New post on Science and Enterprise: NIH Opens Covid-19 Clinical Trial Network https://t.co/kB3fWJO4Kh #Science #Business
    about 6 hours ago
  • From my former Science Careers colleagues ... ‘Disturbing and cruel.’ Universities blast new visa rule for internat… https://t.co/WOI1on7in1
    about 10 hours ago
  • A biotechnology company is receiving European Commission and French government funds to develop vaccines that prote… https://t.co/Ijt0cLCBd0
    about 1 day ago
  • New post on Science and Enterprise: EC, France Fund Universal Covid-19, Flu Vaccines https://t.co/qT6cmb5P1S #Science #Business
    about 1 day ago

Please share Science & Enterprise

Biotech Licenses Brain-Nervous System Treatment Technology

Brain scan (National Institute of Mental Health)

(National Institute of Mental Health)

Ben-Gurion University of the Negev in Israel says it has licensed a technology from its labs that crosses the blood-brain barrier to deliver drugs for treating disorders of the brain and central nervous system. The V-Smart technology, as its called, was licensed exclusively to Lauren Sciences LLC, a privately held biotechnology company in New York.

Lauren Sciences is expected to develop the technology as a platform for treating a variety of diseases that affect the central nervous system, such as Parkinson’s, Alzheimer’s, Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig’s Disease), and brain tumors.

The V-Smart technology uses tiny — 20 to 100 nanometers; 1 nanometer equals 1 billionth of a meter — lipid bubbles called vesicles that can cross the blood-brain barrier to deliver drugs to specific targets in the brain. The nano-vesicles act as building blocks for the delivery of drugs in the desired quantities.

The technology was developed by Ben-Gurion researchers Sabrina Grinberg, Charles Linder, and Eliahu Heldman, who also serves as the chief technology officer of Lauren Sciences. Heldman says their preclinical studies show the nano-scale vesicles, “encapsulate small molecules, peptides, proteins and nucleic acids, cross the [blood-brain barrier] and release their encapsulated contents in the brain.” The researchers say there is an unmet need for a safe, effective, and reliable transport system to deliver chemotherapeutic agents to the brain of patients with brain cancer and other central nervous system disorders.

Lauren Sciences was recently awarded a grant from the Michael J. Fox Foundation to develop a V-Smart treatment for Parkinson’s disease. The university says the V-Smart technology is protected by several worldwide patents filed by BGN Technologies Ltd., its technology transfer office.

Read more: Organic Nanoparticle in Development for Cancer Drug Delivery

*     *     *

Please share Science & Enterprise ...

Comments are closed.